SCHEMBL6270528

SCHEMBL6270528

FC(F)(F)Oc1cc(C(F)(F)F)c2nc(C(F)(F)F)[nH]c2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CACNA1H O95180 7/20 0.41
▸ SYK P43405 1/20 0.40
▸ CACNA1C Q13936 2/20 0.39
▸ CACNA1B Q00975 1/20 0.39
▸ CACNA1G O43497 2/20 0.39
▸ MAPT P10636 3/20 0.39
▸ POLB P06746 2/20 0.39
▸ L3MBTL1 Q9Y468 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.37
▸ KDM4E B2RXH2 5/20 0.36
▸ HPGD P15428 3/20 0.36
▸ HTT P42858 2/20 0.36
▸ HSD17B10 Q99714 2/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ LMNA P02545 1/20 0.36
▸ EGLN1 Q9GZT9 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9676866 0.84 MAPT (0.39) MAPTPOLBL3MBTL1MEN1GAA
SCHEMBL20623233 0.77 CACNA1H (0.62) CACNA1HCACNA1CCACNA1BCACNA1GEGLN1
SCHEMBL8481047 0.76 CSNK2A1 (0.43) CACNA1HSYKCACNA1CCACNA1BCACNA1G
SCHEMBL1873989 0.74 DHODH (0.40) CACNA1HSYKCACNA1CCACNA1GMAPT
SCHEMBL9674405 0.73 KDM4E (0.58) MAPTPOLBL3MBTL1NPSR1KDM4E
SCHEMBL9674984 0.70 NPSR1 (0.53) MAPTPOLBL3MBTL1GAAKMT2A
SCHEMBL8855454 0.70 ALDH1A1 (0.43) CACNA1HSYKCACNA1CCACNA1BCACNA1G
SCHEMBL11827835 0.69 KDM4E (0.49) CACNA1HSYKCACNA1CCACNA1BCACNA1G
SCHEMBL1285685 0.69 CACNA1H (0.46) CACNA1HSYKCACNA1CCACNA1BCACNA1G
SCHEMBL6268930 0.69 KDM4E (0.50) CACNA1HCACNA1CCACNA1GMAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1326845-B1 N-ALKOXYALKYL-SUBSTITUTED BENZIMIDAZOLES AND THE USE THEREOF AS AN AGENT AGAINST PARASITIC PROTOZOANS BAYER HEALTHCARE AG (DE) 2005-12-14 — — EP disclosed
US-20040044055-A1 N-alkoxlyalkyl-substituted benzimidazoles and the use thereof as an agent against parastic protozoans BAYER AKTIENGESELLSCHAFT (DE) 2004-03-04 — — US disclosed
EP-1326845-A1 N-ALKOXYALKYL-SUBSTITUTED BENZIMIDAZOLES AND THE USE THEREOF AS AN AGENT AGAINST PARASITIC PROTOZOANS Bayer Aktiengesellschaft (DE) 2003-07-16 — — EP disclosed
WO-2002030909-A1 N-ALKOXYALKYL-SUBSTITUTED BENZIMIDAZOLES AND THE USE THEREOF AS AN AGENT AGAINST PARASITIC PROTOZOANS BAYER AKTIENGESELLSCHAFT (DE) 2002-04-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044055-A1 N-alkoxlyalkyl-substituted benzimidazoles and the use thereof as an agent against parastic protozoans PIGO, EPX, PIGK CACNA1H 3625/4885SYK 2495/4885CACNA1C 3941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback